v3.26.1
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) - USD ($)
$ in Thousands
Total
Series A Common Stock
Series B Common Stock
Conversion of Common Stock Upon Shareholder Election and Vesting of Certain Equity Awards
Common Stock
Series A Common Stock
Common Stock
Series B Common Stock
Common Stock
Conversion of Common Stock Upon Shareholder Election and Vesting of Certain Equity Awards
Series A Common Stock
Common Stock
Conversion of Common Stock Upon Shareholder Election and Vesting of Certain Equity Awards
Series B Common Stock
Treasury Stock
Additional Paid-In Capital
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2024         88,956,301 183,801,332          
Beginning balance at Dec. 31, 2024 $ 1,033,987       $ 89 $ 184     $ 0 $ 1,878,899 $ (845,185)
Beginning balance (in shares) at Dec. 31, 2024                 0    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Issuance of common stock upon exercise of common stock options (in shares)           920,727          
Issuance of common stock upon exercise of common stock options 877         $ 1       876  
Issuance of common stock upon vesting of restricted stock units (in shares)         885,380 742,420          
Issuance of common stock upon vesting of restricted stock units (1)       $ 1 $ 1       (3)  
Issuance of common stock upon exercise of collaboration agreement warrants (in shares)           344,382          
Issuance of common stock upon exercise of collaboration agreement warrants 3                 3  
Vested warrants related to collaboration agreement 8,100                 8,100  
Stock-based compensation expense 39,434                 39,434  
Tax withholdings on settlement of stock-based awards (in shares)         (47,175) (45,997)          
Tax withholdings on settlement of stock-based awards (4,379)                 (4,379)  
Conversion of Series B common stock to Series A common stock upon shareholder election and vesting of certain equity awards (in shares)             4,779,530 (4,779,530)      
Conversion of Series B common stock to Series A common stock upon shareholder election and vesting of certain equity awards       $ 0     $ 5 $ (5)      
Net income (loss) (14,089)                   (14,089)
Ending balance (in shares) at Mar. 31, 2025         94,574,036 180,983,334          
Ending balance at Mar. 31, 2025 1,063,932       $ 95 $ 181     $ 0 1,922,930 (859,274)
Ending balance (in shares) at Mar. 31, 2025                 0    
Beginning balance (in shares) at Dec. 31, 2025   144,262,443 159,899,668   144,262,443 159,899,668          
Beginning balance at Dec. 31, 2025 $ 1,196,560       $ 144 $ 160     $ 0 2,073,209 (876,953)
Beginning balance (in shares) at Dec. 31, 2025 0               0    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Issuance of common stock upon exercise of common stock options (in shares)           789,629          
Issuance of common stock upon exercise of common stock options $ 715         $ 1       714  
Issuance of common stock upon vesting of restricted stock units (in shares)         1,212,824 508,278          
Issuance of common stock upon vesting of restricted stock units (1)       $ 1         (2)  
Issuance of common stock upon exercise of collaboration agreement warrants (in shares)           344,383          
Issuance of common stock upon exercise of collaboration agreement warrants 3                 3  
Vested warrants related to collaboration agreement 8,100                 8,100  
Stock-based compensation expense 42,657                 42,657  
Tax withholdings on settlement of stock-based awards (in shares)         (95,310) (75,244)          
Tax withholdings on settlement of stock-based awards (2,800)                 (2,800)  
Conversion of Series B common stock to Series A common stock upon shareholder election and vesting of certain equity awards (in shares)             3,009,779 (3,009,779)      
Conversion of Series B common stock to Series A common stock upon shareholder election and vesting of certain equity awards       $ 0     $ 3 $ (3)      
Share repurchases, inclusive of costs to acquire (in shares)         (4,307,869)       (4,307,869)    
Share repurchases, inclusive of costs to acquire (100,813)       $ (4)       $ 4 (100,813)  
Net income (loss) 9,038                   9,038
Ending balance (in shares) at Mar. 31, 2026   144,081,867 158,456,935   144,081,867 158,456,935          
Ending balance at Mar. 31, 2026 $ 1,153,459       $ 144 $ 158     $ 4 $ 2,021,068 $ (867,915)
Ending balance (in shares) at Mar. 31, 2026 4,307,869               4,307,869